Autor: |
Noelle N. Gronroos, Caroline Swift, Monica S. Frazer, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J. Dunn, Josh Noone |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Journal of Health Economics and Outcomes Research, Vol 11, Iss 2 (2024) |
Druh dokumentu: |
article |
ISSN: |
2327-2236 |
DOI: |
10.36469/001c.124111 |
Popis: |
**Background:** Medical management of patients with type 2 diabetes mellitus (T2DM) is complex because of the chronic nature of the disease and its associated comorbidities. Injectable once-weekly semaglutide for diabetes (OW sema T2D) is a type of glucagon-like peptide–1 receptor agonist approved for the treatment of patients with T2DM. **Objectives:** To describe patient characteristics and HbA1c changes for patients prescribed 1.0 mg maintenance dose OW sema T2D. **Methods:** This retrospective study included adult patients with T2DM with a pre-index glycated hemoglobin (HbA1c) of at least 7%, initiating treatment with OW sema T2D between January 1, 2018, and December 31, 2019, and prescribed a 1.0 mg maintenance dose. Patients were identified in the Optum Research Database and were included if they had continuous health plan enrollment for at least 12 months prior to (pre-index) and at least 12 months following (post-index) the date of the first OW sema T2D claim (index). Dose at initiation and prescriber specialty were captured. Change in HbA1c between the latest post-index and pre-index HbA1c measurement was calculated among all patients and among those with at least 90 days of continuous treatment (persistent patients). **Results:** A total of 2168 patients were included in this study. On average, patients were taking 13.5 different classes of medications. The majority of patients had lipid metabolism disorder (90.8%), hypertension (86.6%), diabetes with complications (86.8%), or other nutritional/endocrine/metabolic disorders (72.5%). The mean HbA1c reduction was 1.2% (P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|